Cover Page

The handle http://hdl.handle.net/1887/86285 holds various files of this Leiden University dissertation.

Bibliography

[1] Adjuvant! online program. `https://www.adjuvantonline.com`.

[2] Data analysis and survival for personalised oncology. `https://sites.google.com/view/daspo`.

[3] Mayo Clinic soft tissue sarcoma. `https://www.mayoclinic.org/diseases-conditions/soft-tissue-sarcoma/symptoms-causes/syc-20377725`. Accessed: 12-10-2019.

[4] Personalised sarcoma care, apple store. `https://apps.apple.com/nl/app/personalized-sarcoma-care/id1189577003`.

[5] Personalised sarcoma care, google play store. `https://play.google.com/store/apps/details?id=com.mobilepioneers.sarcoma&hl=en`.

[6] Predict tool version 2.0: Breast cancer overall survival. `https://www.predict.nhs.uk`.

[7] Prostate cancer nomograms. `https://www.mskcc.org/nomograms/prostate`.

[8] Protocol: Euro ewing 99. european ewing tumour working initiative of national groups, ewing tumour studies 1999/ee99; euro ewing 99, 2006.

[9] A. K. Akobeng. Understanding diagnostic tests 3: receiver operating characteristic curves. *Acta Paediatr*, 96(5):644–647, 2007.

[10] E. Al-Absi, F. Farrokhyar, R. Sharma, K. Whelan, T. Corbett, M. Patel, and M. Ghert. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. *Ann Surg Oncol*, 17(5):1367–1374, 2010.

[11] J. I. Albergo, C. L. Gaston, M. Laitinen, A. Darbyshire, L. M. Jeys, V. Sumathi, M. Parry, D. Peake, S. R. Carter, R. Tillman, A. T. Abudu, and R. J. Grimer. Ewing's sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response. *Bone Joint J*, 98-B(8):1138–1144, 2016.

[12] P. Andersen and N. Keiding. Multi-state models for event history analysis. *Stat Methods Med Res*, 11(2):91–115, 2002.

[13] J. R. Anderson, K. C. Cain, and R. D. Gelber. Analysis of survival by tumor response. *J Clin Oncol*, 1(11):710–719, 1983.

[14] **A. J. Rueten-Budde**, S. Bosma, C. Lancia, A. Ranft, U. Dirksen, Krol, H. Gelderblom, M. van de Sande, P. Dijkstra, and M. Fiocco. Individual risk evaluation for local recurrence and distant metastasis in ewing sarcoma: a multistate model. *Pediatr Blood Cancer*, 66(e27943):doi: 10.1002/pbc.27943, 2019.

[15] **A. J. Rueten-Budde**, C. Liu, A. Ranft, U. Dirksen, H. Gelderblom, and M. Fiocco. Dynamic prediction of overall survival for patients with ewing sarcoma. *Submitted*.

[16] **A. J. Rueten-Budde**, H. Putter, and M. Fiocco. Assessment of predictive accuracy of an intermittenly observed binary time-dependent marker. *Submitted*.

[17] **A. J. Rueten-Budde**, H. Putter, and M. Fiocco. Investigating hospital heterogeneity with a competing risks frailty model. *Stat Med*, 38(2):269–288, 2018.

[18] **A. J. Rueten-Budde**, M. van de Sande, V. van Praag, PERSARC studygroup, and M. Fiocco. External validation and adaptation of a dynamic prediction model for patients with high-grade extremity soft tissue sarcoma. *Submitted*.

[19] **A. J. Rueten-Budde**, V. van Praag, PERSARC studygroup, M. van de Sande, and M. Fiocco. Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. *Surg Oncol*, 27(4):695–701, 2018.

[20] **A. J. Rueten-Budde**, V. M. van Praag, L. M. Jeys, M. K. Laitinen, R. Pollock, W. Aston, J. A. van der Hage, P. S. Dijkstra, P. C. Ferguson, A. M. Griffin, J. J. Willeumier, J. S. Wunder, M. A. van de Sande, and M. Fiocco. A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: personalised sarcoma care (persarc). *Eur J Cancer*, 83:313–323, 2017.

[21] **A. J. Rueten-Budde**, J. J. Willeumier, L. M. Jeys, M. Laitinen, R. Pollock, W. Aston, P. D. S. Dijkstra, P. C. Ferguson, A. M. Griffin, J. S. Wunder, M. Fiocco, and M. A. J. van de Sande. Individualised risk assessment for local recurrence and distant metastases in a retrospective transatlantic cohort of 687 patients with high-grade soft tissue sarcomas of the extremities: a multistate model. *BMJ Open*, 7(2):e012930, 2017.

[22] E. Arpaci, T. Yetisyigit, M. Seker, D. Uncu, U. Üyetürk, B. Oksuzoglu, U. Demirci, U. Coskun, M. Kucukoner, A. Isikdogan, M. Inanc, N. Alkis, and M. Ozkan. Prognostic factors and clinical outcome of patients with ewing's sarcoma family of tumors in adults: Multicentric study of the anatolian society of medical oncology. *Med Oncol*, 30(1):469, 2013.

[23] I. Atean, Y. Pointreau, P. Rosset, P. Garaud, G. De-Pinieux, and G. Calais. Prognostic factors of extremity soft tissue sarcoma in adults. a single institutional analysis. *Cancer/Radiother*, 16(8):661–666, 2012.

[24] P. C. Austin and J. P. Fine. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. *Stat Med*, 36(8):1203–1209, 2017.

[25] G. Bacci, S. Ferrari, A. Longhi, D. Donati, E. Barbieri, C. Forni, F. Bertoni, M. Manfrini, S. Giacomini, and P. Bacchini. Role of surgery in local treatment of ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. *Oncol Rep*, 11(1):111–120, 2004.

[26] G. Bacci, A. Longhi, A. Briccoli, F. Bertoni, M. Versari, and P. Picci. The role of surgical margins in treatment of ewing's sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. *Int J Radiat Oncol Biol Phys*, 65(3):766–772, 2006.

[27] T. Balan and H. Putter. *frailtyEM: an R package for estimating semiparametric shared frailty models*, 2017. R package version 0.7.9.

[28] J. D. Beane, J. C. Yang, D. White, S. M. Steinberg, S. A. Rosenberg, and U. Rudloff. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. *Ann Surg Oncol*, 21(8):2484–2489, 2014.

[29] D. J. Biau, P. C. Ferguson, P. Chung, A. M. Griffin, C. N. Catton, B. O'Sullivan, and J. S. Wunder. Local recurrence of localized soft tissue sarcoma: a new look at old predictors. *Cancer*, 118(23):5867–5877, 2012.

[30] B. Biswas, S. Rastogi, S. Khan, N. Shukla, S. Deo, S. Agarwala, B. Mohanti, M. Sharma, S. Vishnubhatla, and S. Bakhshi. Developing a prognostic model for localized ewing sarcoma family of tumors: a single institutional experience of 224 cases treated with uniform chemotherapy protocol. *J Surg Oncol*, 111(6):683–689, 2015.

[31] A. Boruvka and R. Cook. Sieve estimation in a markov illness-death process under dual censoring. *Biostatistics*, 17(2):350–363, 2016.

[32] S. Bosma, C. Lancia, **A. J. Rueten-Budde**, A. Ranft, H. Gelderblom, M. Fiocco, M. van de Sande, P. Dijkstra, and U. Dirksen. Easy-to-use clinical tool for survival estimation in ewing sarcoma at diagnosis and after surgery. *Sci Rep*, 9(11000), 2019.

[33] M. F. Brennan, E. S. Casper, L. B. Harrison, M. H. Shiu, J. Gaynor, and S. I. Hajdu. *Ann Surg*, 214(3):328–338, 1991.

[34] N. Breslow. Covariance analysis of censored survival data. *Biometrics*, 30(1):89–99, 1974.

[35] O. Cahlon, M. F. Brennan, X. Jia, L.-X. Qin, S. Singer, and K. M. Alektiar. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. *Ann Surg*, 255(2):343–347, 2012.

[36] D. Callegaro, R. Miceli, S. Bonvalot, P. Ferguson, D. C. Strauss, and A. Levy. Impact of perioperative chemotherapy and radiotherapy in patients with

primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. *Eur J Cancer*, 105:19–27, 2018.

[37] D. Callegaro, R. Miceli, S. Bonvalot, P. Ferguson, D. C. Strauss, A. Levy, A. Griffin, A. J. Hayes, S. Stacchiotti, C. L. Pechoux, M. J. Smith, M. Fiore, A. P. D. Tos, H. G. Smith, L. Mariani, J. S. Wunder, R. E. Pollock, P. G. Casali, and A. Gronchi. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. *Lancet Oncol*, 17(5):671–680, 2016.

[38] A. Carneiro, P.-O. Bendahl, J. Engellau, H. A. Domanski, C. D. Fletcher, P. Rissler, A. Rydholm, and M. Nilbert. A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. *Cancer*, 117(6):1279–1287, 2011.

[39] G. Casella and R. Berger. *Statistical Inference*. Duxbury Press, 2001.

[40] D. Clayton. A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. *Biometrika*, 65(1):141–151, 1978.

[41] J. Coindre, P. Terrier, N. Bui, F. Bonichon, F. Collin, V. Le Doussal, A. Mandard, M. Vilain, J. Jacquemier, H. Duplay, X. Sastre, C. Barlier, M. Henry-Amar, J. Macé-Lesech, and G. Contesso. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. a study of 546 patients from the french federation of cancer centers sarcoma group. *J Clin Oncol*, 14(3):869–877, 1996.

[42] G. S. Collins, J. B. Reitsma, D. G. Altman, and K. G. Moons. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (tripod): the tripod statement. *Ann Int Med*, 162(1):55–63, 2015.

[43] S. Cotterill, S. Ahrens, M. Paulussen, H. Jürgens, P. Voûte, H. Gadner, and A. Craft. Prognostic factors in ewing's tumor of bone: analysis of 975 patients from the european intergroup cooperative ewing's sarcoma study group. *J Clin Oncol*, 18(17):3108–3114, 2000.

[44] D. Cox. Regression models and life-tables. *J Royal Stat Soc*, 34(2):187–220, 1972.

[45] L. Davis and C. Ryan. Preoperative therapy for extremity soft tissue sarcomas. *Curr Treat Options Oncol*, 16(6):25, 2015.

[46] G. de Bock, H. Putter, J. Bonnema, J. van der Hage, H. Bartelink, and C. van de Velde. The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. *Breast Cancer Res Treat*, 117(2):401–408, 2009.

[47] N. A. de Glas, E. Bastiaannet, C. C. Engels, A. J. M. de Craen, H. Putter, C. J. H. van de Velde, A. Hurria, G. J. Liefers, and J. E. A. Portielje. Validity of the online predict tool in older patients with breast cancer: a population-based study. *Br J Cancer*, 114(4):395–400, 2016.

[48] L. de Wreede, M. Fiocco, and H. Putter. mstate: An r package for the analysis of competing risks and multi-state models. *J Stat Softw*, 38(7):1–30, 2011.

[49] L. C. de Wreede, M. Fiocco, and H. Putter. The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. *Comput Methods Programs Biomed*, 99(3):261–274, 2010.

[50] A. Dempster, N. Laird, and D. Rubin. Maximum likelihood from incomplete data via the em algorithm. *J Royal Stat Soc*, 39(1):1–38, 1977.

[51] S. Dixon, G. Darlington, and A. Desmond. A competing risks model for correlated data based on the subdistribution hazard. *Lifetime Data Anal*, 17(4):473–495, 2011.

[52] K. R. Duchman, Y. Gao, and B. J. Miller. Prognostic factors for survival in patients with ewing's sarcoma using the surveillance, epidemiology, and end results (seer) program database. *Cancer Epidemiol*, 39(2):189–195, 2015.

[53] F. Eilber, G. Rosen, S. Nelson, M. Selch, F. Dorey, J. Eckardt, and F. Eilber. High-grade extremity soft tissue sarcomas: Factors predictive of local recurrence and its effect on morbidity and mortality. *Ann Surg*, 237(2):218–226, 2003.

[54] J. Engellau, V. Samuelsson, H. Anderson, B. Bjerkehagen, P. Rissler, K. Sundby-Hall, and A. Rydholm. Identification of low-risk tumours in histological high-grade soft tissue sarcomas. *Eur J Cancer*, 43(13):1927–1934, 2007.

[55] W. Enneking, S. Spanier, Goodman, and MA. A system for the surgical staging of musculoskeletal sarcoma. *Clin Orthop Relat Res*, 153:106–120, 1980.

[56] ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 25(suppl_3):iii102–iii112, 2014.

[57] P. Fine and R. Gray. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*, 94(446):496–509, 1999.

[58] M. Fiocco, H. Putter, and J. van Houwelingen. Meta-analysis of pairs of survival curves under heterogeneity: a poisson correlated gamma-frailty approach. *Stat Med*, 28(30):3782–3797, 2009.

[59] M. Fiocco, H. Putter, and J. van Houwelingen. A new serially correlated gamma-frailty process for longitudinal count data. *Biostatistics*, 10(2):245–257, 2009.

[60] T. R. Fleming and D. Y. Lin. Survival analysis in clinical trials : past developments and future directions. *Biometrics*, 56(4):971–983, 2000.

[61] C. Fletcher, P. H. J.A. Bridge, and F. Mertens. *WHO Classification of Tumours of Soft Tissue and Bone.* WHO, 2013.

[62] D. B. Y. Fontein, M. Klinten Grand, J. W. R. Nortier, C. Seynaeve, E. Meershoek-Klein Kranenbarg, L. Y. Dirix, C. J. H. van de Velde, and H. Putter. Dynamic prediction in breast cancer: proving feasibility in clinical practice using the team trial. *Ann Oncol*, 26(6):1254–1262, 2015.

[63] S. Foulon, B. Brennan, N. Gaspar, U. Dirksen, L. Jeys, A. Cassoni, L. Claude, B. Seddon, P. Marec-berard, J. Whelan, M. Paulussen, A. Streitbuerger, O. Oberlin, H. Juergens, R. Grimer, and M.-C. Le Deley. Can postoperative radiotherapy be omitted in localised standard-risk ewing sarcoma? an observational study of the euro-e.w.i.n.g group. *Eur J Cancer*, 61:128–136, 2016.

[64] H. Frydman. Nonparametric estimation of a markov 'illness-death' process from interval-censored observations, with application to diabetes survival data. *Biometrika*, 82(4):773–789, 1995.

[65] H. Frydman and M. Szarek. Nonparametric estimation in a markov 'illness-death' process from interval censored observations with missing intermediate transition status. *Biometrics*, 65(1):143–151, 2009.

[66] P. G Casali, N. Abecassis, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J. Bovee, T. Brodowicz, J. Martin-Broto, A. Buonadonna, E. De Álava, A. Tos, X. G Del Muro, P. Dileo, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, and J.-Y. Blay. Soft tissue and visceral sarcomas: Esmo-euracan clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 29(Supplement_4):iv51–iv67, 2018.

[67] N. Gaspar, A. Rey, P. Marec-berard, J. Michon, J.-C. Gentet, M.-D. Tabone, H. Roché, A. Defachelles, O. Lejars, E. Plouvier, C. Schmitt, B. Bui, P. Boutard, S. Taque, M. Munzer, J.-P. Vannier, D. Plantaz, N. Entz-Werle, and O. Oberlin. Risk adapted chemotherapy for localised ewing's sarcoma of bone: the french ew93 study. *Eur J Cancer*, 48(9):1376–1385, 2012.

[68] N. Gaspar, D. S Hawkins, U. Dirksen, I. J Lewis, S. Ferrari, M.-C. Le Deley, H. Kovar, R. Grimer, J. Whelan, L. Claude, O. delattre, M. Paulussen, P. Picci, K. Hall, H. van den Berg, R. Ladenstein, J. Michon, L. Hjorth, I. Judson, and O. Oberlin. Ewing sarcoma: current management and future approaches through collaboration. *J Clin Oncol*, 33(27):3036–3046, 2015.

[69] P. Gilbert and R. Varadhan. *numDeriv: Accurate Numerical Derivatives*, 2016. R package version 2016.8-1.

[70] J. P. Ginsberg, P. Goodman, W. Leisenring, K. K. Ness, P. A. Meyers, S. L. Wolden, S. M. Smith, M. Stovall, S. Hammond, L. L. Robison, and K. C. Oeffinger. Long-term survivors of childhood ewing sarcoma: report from the childhood cancer survivor study. *J Natl Cancer Inst*, 102(16):1272–1283, 2010.

[71] H. Goldstein and D. Spiegelhalter. League tables and their limitations: statistical issues in comparisons of institutional performance. *J Royal Stat Soc*, 159:385–443, 1996.

[72] M. Gorfine and L. Hsu. Frailty-based competing risks model for multivariate survival data. *Biometrics*, 67(2):415–426, 2011.

[73] A. Gronchi, P. Casali, L. Mariani, R. Miceli, M. Fiore, S. Lo Vullo, R. Bertulli, P. Collini, L. Lozza, P. Olmi, and J. Rosai. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: A series of patients treated at a single institution. *J Clin Oncol*, 23(1):96–104, 2005.

[74] A. Gronchi, S. Lo Vullo, C. Colombo, P. Collini, S. Stacchiotti, L. Mariani, M. Fiore, and P. G. Casali. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. *Ann Surg*, 251(3):506–511, 2010.

[75] W. M. Guerrero and J. L. Deneve. Local recurrence of extremity soft tissue sarcoma. *Surg Clin North Am*, 96(5):1157–1174, 2016.

[76] K. R. Gundle, L. Kafchinski, S. Gupta, A. M. Griffin, B. C. Dickson, P. W. Chung, C. N. Catton, B. O'Sullivan, J. S. Wunder, and P. C. Ferguson. Analysis of margin classification systems for assessing the risk of local recurrence after soft tissue sarcoma resection. *J Clin Oncol*, 36(7):704–709, 2018.

[77] P. Gustafson, M. Åkerman, T. Alvegård, J.-M. Coindre, C. Fletcher, A. Rydholm, and H. Willé n. Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis-the sin-system. *Eur J Cancer*, 39(11):1568–1576, 2003.

[78] F. Harrell, K. Lee, and D. Mark. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*, 15:361–387, 1996.

[79] P. Heagerty, T. Lumley, and M. Pepe. Time-dependent roc curves for censored survival data and a diagnostic marker. *Biometrics*, 56:337–344, 2000.

[80] P. Heagerty and Y. Zheng. Survival model predictive accuracy and roc curves. *Biometrics*, 61(1):92–105, 2005.

[81] K. Hoang, . Yubo Gao, PhD, and M. Benjamin J. Miller, MD. The variability in surgical margin reporting in limb salvage surgery for sarcoma. *Iowa Orthop J*, 35(1):181–186, 2015.

[82] J. Honaker, G. King, and M. Blackwell. Amelia ii: a program for missing data. *J Stat Softw*, 45(7):1–54, 2011.

[83] A. Italiano, A. Le Cesne, J. Mendiboure, J. Blay, S. Piperno-Neumann, C. Chevreau, C. Delcambre, N. Penel, P. Terrier, D. Ranchere-Vince, M. Lae,

S. Le Guellec, J. Michels, Y. Robin, C. Bellera, and S. Bonvalot. Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting. *Cancer*, 120(21):3361–3369, 214.

[84] B. J Miller, Y. Gao, and K. R Duchman. Does surgery or radiation provide the best overall survival in ewing's sarcoma? a review of the national cancer data base. *J Surg Oncol*, 116(3):384–390, 2017.

[85] C. Jackson. Multi-state models for panel data: The msm package for r. *J Stat Softw*, 38(8), 2011.

[86] P. Joly, D. Commenges, C. Helmer, and L. Letenneur. A penalized likelihood approach for an illness-death model with interval-censored data : application to age-specific incidence of dementia. *Biostatistics*, 3(3):433–443, 2002.

[87] V. Kainhofer, M. Smolle, J. Szkandera, B. Liegl-Atzwanger, W. Maurer-Ertl, A. Gerger, J. Riedl, and A. Leithner. The width of resection margins influences local recurrence in soft tissue sarcoma patients. *Eur J Surg Oncol*, 42(6):899–906, 2016.

[88] E. L. Kaplan and P. Meier. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*, 53(282):457–481, 1958.

[89] S. Katsahian, S. C. M Resche-Rigon, and R. Porcher. Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution. *Stat Med*, 25(24):4267–4278, 2006.

[90] N. Kawaguchi, A. Ahmed, S. Matsumoto, J. Manabe, and Y. Matsushita. The concept of curative margin in surgery for bone and soft tissue sarcoma. *Clin Orthop Relat Res*, 419:165–172, 2004.

[91] N. Kawaguchi, S. Matumoto, and J. Manabe. New method of evaluating the surgical margin and safety margin for musculoskeletal sarcoma, analysed on the basis of 457 surgical cases", journal="journal of cancer research and clinical oncology. *Journal of Cancer Research and Clinical Oncology*, 121(9):555–563, 1995.

[92] J. P. Klein and M. L. Moeschberger. *Survival Analysis*. Springer, 1997.

[93] M. T. Koller, H. Raatz, E. W. Steyerberg, and M. Wolbers. Competing risks and the clinical community: irrelevance or ignorance? *Stat Med*, 31:1089–1097, 2012.

[94] T. Kuklo, H. Temple, B. Owens, J. Juliano, R. Islinger, Y. Andejeski, D. Frassica, and B. Berrey. Preoperative versus postoperative radiation therapy for soft-tissue sarcomas. *Am J Orthop (Belle Mead NJ)*, 34(2):75–80, 2005.

[95] R. Ladenstein, U. Pötschger, M. Cécile Le Deley, J. Whelan, M. Paulussen, O. Oberlin, H. van den Berg, U. Dirksen, L. Hjorth, J. Michon, I. Lewis, A. Craft, and H. Juergens. Primary disseminated multifocal ewing sarcoma: results of the euro-ewing 99 trial. *J Clin Oncol*, 28(20):3284–3291, 2010.

[96] J. Lee, B. H. Hoang, A. Ziogas, and J. A. Zell. Analysis of prognostic factors in ewing sarcoma using a population-based cancer registry. *Cancer*, 116(8):1964–1973, 2010.

[97] K. Leffondré, C. Touraine, C. Helmer, and P. Joly. Interval-censored time-to-event and competing risk with death: is the illness-death model more accurate than the cox model? *Int J Epidemiol*, 42(4):1177–1186, 2013.

[98] J. J. Lewis, D. Leung, M. Heslin, J. M. Woodruff, and M. F. Brennan. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma. *J Clin Oncol*, 15(2):646–652, 1997.

[99] B. Liquet, J. Timsit, and V. Rondeau. Investigating hospital heterogeneity with a multi-state frailty model: application to nosocomial pneumonia disease in intensive care units. *BMC Med Res Methodol*, 12(79):doi: 10.1186/1471–2288–12–79, 2012.

[100] R. Little and D. Rubin. *Multiple Imputation for Nonresponse in Surveys, 2nd Edition*. Wiley, 2002.

[101] T. Louis. Finding the observed information matrix when using the em algorithm. *J Royal Stat Soc*, 44(2):226–233, 1982.

[102] K. Maretty-Nielsen, N. Aggerholm-Pedersen, A. Safwat, P. H. J. rgensen, B. H. Hansen, S. Baerentzen, A. B. Pedersen, and J. Keller. Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients. *Acta Orthop*, 85(3):323–332, 2014.

[103] L. Mariani, R. Miceli, M. W. Kattan, M. F. Brennan, M. Colecchia, M. Fiore, P. G. Casali, and A. Gronchi. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. *Cancer*, 103(2):402–408, 2005.

[104] M. Mastboom, E. Staals, F. Verspoor, **A. J. Rueten-Budde**, S. Stacchiotti, E. Palmerini, G. Schaap, P. Jutte, W. Aston, A. Leithner, D. Dammerer, A. Takeuchi, Q. Thio, X. Niu, J. Wunder, TGCT study group, and M. van de Sande. Surgical treatment of localized-type tenosynovial giant cell tumours of large joints. *J Bone Joint Surg*, 101(14):1309–1318, 2019.

[105] M. J. L. Mastboom, E. Palmerini, F. G. M. Verspoor, **A. J. Rueten-Budde**, S. Stacchiotti, E. L. Staals, G. R. Schaap, P. C. Jutte, W. Aston, H. Gelderblom, A. Leithner, D. Dammerer, A. Takeuchi, Q. Thio, X. Niu, J. S. Wunder, TGCT Study Group, and M. A. J. van de Sande. Surgical outcomes of patients with

diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. *Lancet Oncol*, 20(6):877–886, 2019.

[106] M. D. Mc Kee, D. F. Liu, J. J. Brooks, J. F. Gibbs, D. L. Driscoll, and W. G. Kraybill. The prognostic significance of margin width for extremity and trunk sarcoma. *J Surg Oncol*, 85(2):68–76, 2004.

[107] W. Mendenhall, D. Indelicato, M. Scarborough, R. Zlotecki, C. Gibbs, N. Mendenhall, C. Mendenhall, and W. Enneking. The management of adult soft tissue sarcomas. *Am J Clin Oncol*, 32(4):436–442, 2009.

[108] D. Müller, G. Beltrami, G. Scoccianti, F. Frenos, and R. Capanna. Combining limb-sparing surgery with radiation therapy in high-grade soft tissue sarcoma of extremities - is it effective? *Eur J Surg Oncol*, 42(7):1057–1063, 2016.

[109] G. G. Nielsen, R. D. Gill, P. K. Andersen, and T. I. Sørensen. A counting process approach to maximum likelihood estimation in frailty models. *Scand J Stat*, 19(1):25–43, 1992.

[110] E. N. Novais, B. Demiralp, J. Alderete, M. C. Larson, P. S. Rose, and F. H. Sim. Do surgical margin and local recurrence influence survival in soft tissue sarcomas? *Clin Orthop Relat Res*, 468(11):3003–3011, 2010.

[111] P. W. O'Donnell, A. M. Griffin, W. C. Eward, A. Sternheim, C. N. Catton, P. W. Chung, B. O'Sullivan, P. C. Ferguson, and J. S. Wunder. The effect of the setting of a positive surgical margin in soft tissue sarcoma. *Cancer*, 120(18):2866–2875, 2014.

[112] B. O'Sullivan, A. M. Davis, R. Turcotte, R. Bell, C. Catton, P. Chabot, J. Wunder, R. Kandel, K. Goddard, A. Sadura, J. Pater, and B. Zee. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. *Lancet*, 359(9325):2235–2241, 2002.

[113] T. Ozaki M.D, A. Hillmann, C. Hoffmann, C. Rübe M.D, S. Blasius M.D, J. Dunst, H. Jürgens, and W. Winkelmann M.D. Significance of surgical margin on the prognosis of patients with ewing's sarcoma: a report from the cooperative ewing's sarcoma study. *Cancer*, 78(4):892–900, 1996.

[114] S. Pasquali, C. Colombo, S. Pizzamiglio, P. Verderio, D. Callegaro, S. Stacchiotti, J. Martin Broto, A. Lopez-Pousa, S. Ferrari, A. Poveda, A. De Paoli, V. Quagliuolo, J. C. Jurado, A. Comandone, G. Grignani, R. De Sanctis, E. Palassini, A. Llomboart-Bosch, A. P. Dei Tos, P. G. Casali, P. Picci, and A. Gronchi. High-risk soft tissue sarcomas treated with perioperative chemotherapy: improving prognostic classification in a randomised clinical trial. *Eur J Cancer*, 93:28–36, 2018.

[115] S. Pasquali, S. Pizzamiglio, N. Touati, S. Litiere, S. Marreaud, B. Kasper, H. Gelderblom, S. Stacchiotti, I. Judson, A. P. Dei Tos, P. Verderio, P. G. Casali, P. J. Woll, A. Gronchi, E.-S. Tissue, and B. S. Group. The impact of

chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the eortc-stbsg 62931 randomised trial. *Eur J Cancer*, 109:51–60, 2019.

[116] J. Petersen, P. Andersen, and R. Gill. Variance components models for survival data. *Stat Neerl*, 50:193–211, 1996.

[117] P. Pisters, D. Leung, J. Woodruff, W. Shi, and M. Brennan. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. *J Clin Oncol*, 14(5):1679–1689, 1996.

[118] E. M. Pullenayegum, R. W. Platt, M. Barwick, B. M. Feldman, M. Offringa, and L. Thabane. Knowledge translation in biostatistics: a survey of current practices, preferences, and barriers to the dissemination and uptake of new statistical methods. *Stat Med*, 35(6):805–818, 2016.

[119] H. Putter, M. Fiocco, and R. B. Geskus. Tutorial in biostatistics: competing risks and multi-state models. *Stat Med*, 26(11):2389–2430, 2007.

[120] H. Putter and J. van Houwelingen. Dynamic frailty models based on compound birth-death processes. *Biostatistics*, 16(3):550–564, 2015.

[121] H. Putter and J. van Houwelingen. Frailties in multi-state models: are they identifiable? do we need them? *Stat Methods Med Res*, 24(6):675–692, 2015.

[122] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2018.

[123] F. Rotolo, V. Rondeau, and C. Legrand. Incorporation of nested frailties into semiparametric multi-state models. *Stat Med*, 35(4):609–621, 2016.

[124] P. Royston and D. G. Altman. External validation of a cox prognostic model: principles and methods. *BMC Med Res Methodol*, 13:33, 2013.

[125] D. Rubin. *Multiple Imputation for Nonresponse in Surveys*. Wiley, 1987.

[126] D. B. Rubin. Multiple imputation after 18+ years. *J Am Stat Assoc*, 91(434):473–489, 1996.

[127] S. Sampath, T. E. Schultheiss, Y. J. Hitchcock, R. L. Randall, D. C. Shrieve, and J. Y. Wong. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients. *Int J Radiat Oncol Biol Phys*, 81(2):498–505, 2011.

[128] M. Sampo, M. Tarkkanen, E. Tukiainen, P. Popov, P. Gustafson, M. Lundin, T. Böhling, C. Blomqvist, and J. Lundin. A web-based prognostic tool for extremity and trunk wall soft tissue sarcomas and its external validation. *Br J Cancer*, 106(6):1076–1082, 2012.

[129] J. L. Schafer. *Analysis of Incomplete Multivariate Data*. Chapman & Hall, 1997.

[130] J. L. Schafer and M. K. Olsen. Multiple imputation for multivariate missing-data problems: A data analyst's perspective. *Multivar Behav Res*, 33(4):545–571, 1998.

[131] T. Scheike, Y. Sun, M. Zhang, and T. Jensen. A semiparametric random effects model for multivariate competing risks data. *Biometrika*, 97(1):133–145, 2010.

[132] M. J. Schell. Identifying key statistical papers from 1985 to 2002 using citation data for applied biostatisticians. *Am Stat*, 64(4):310–317, 2010.

[133] M. Schemper and T. L. Smith. A note on quantifying follow-up in studies of failure time. *Controlled Clin Trials*, 17(4):343–346, 1996.

[134] A. Schuck, S. Ahrens, M. Paulussen, M. Kuhlen, S. Könemann, C. Rübe, W. Winkelmann, R. Kotz, J. Dunst, N. Willich, and H. Jürgens. Local therapy in localized ewing tumors: results of 1058 patients treated in the cess 81, cess 86, and eicess 92 trials. *Int J Radiat Oncol Biol Phys*, 55(1):168–177, 2003.

[135] E. Schutgens, P. Picci, D. Baumhoer, R. Pollock, J. Bovee, P. Hogendoorn, P. Dijkstra, **A. J. Rueten-Budde**, P. Jutte, F. Traub, A. Leithner, P. Tunn, P. Funovics, G. Sys, M. Julian, G. Schaap, H. Dürr, J. Hardes, J. Healy, R. Capanna, D. Biau, A. Gomez-Brouchet, J. Wunder, T. Cosker, M. Laitinen, X. Niu, V. Kostiuk, Adamantinoma research group, and M. van de Sande. Surgical outcome and oncological survival of osteofibrous dysplasia-like- and classic adamantinoma: an international multicenter study of 318 cases. *Submitted*.

[136] G. Shankar, C. R Pinkerton, A. Atra, S. Ashley, I. Lewis, D. Spooner, S. Cannon, R. Grimer, S. Cotterill, and A. Craft. Local therapy and other factors influencing site of relapse in patients with localised ewing's sarcoma. united kingdom children's cancer study group (ukccsg). *Eur J Cancer*, 35(12):1698–704, 1999.

[137] R. Siegel, D. Naishadham, and A. Jemal. Cancer statistics, 2013. *CA: A Cancer Journal for Clinicians*, 63(1):11–30, 2013.

[138] J. A. C. Sterne, I. R. White, J. B. Carlin, M. Spratt, P. Royston, M. G. Kenward, A. M. Wood, and J. R. Carpenter. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ*, 338:b2393, 2009.

[139] A. Stojadinovic, D. H. Y. Leung, A. Hoos, D. P. Jaques, J. J. Lewis, and M. F. Brennan. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. *Ann Surg*, 235(3):424–434, 2002.

[140] K. K. Tanabe, R. E. Pollock, L. M. Ellis, A. Murphy, N. Sherman, and M. M. Romsdahl. Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. *Cancer*, 73(6):1652–1659, 1994.

[141] Terry M. Therneau and Patricia M. Grambsch. *Modeling Survival Data: Extending the Cox Model*. Springer, New York, 2000.

[142] T. Therneau. *A package for survival analysis in s*, 2015. R package version 2.38.

[143] N. Thomas, N. Longford, and J. Rolph. Empirical bayes methods for estimating hospital-specific mortality rates. *Stat Med*, 13(9):889–903, 1994.

[144] C. Touraine, T. Gerds, and P. Joly. Smoothhazard: An r package for fitting regression models to interval-censored observations of illness-death models. *J Stat Softw*, 79(7), 2017.

[145] M. Trojani, G. Contesso, J. M. Coindre, J. Rouesse, N. B. Bui, A. De Mascarel, J. F. Goussot, M. David, F. Bonichon, and C. Lagarde. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. *Int J Cancer*, 33(1):37–42, 1984.

[146] C. Trovik, H. Bauer, T. Alvegård, H. Anderson, C. Blomqvist, O. Berlin, P. Gustafson, G. Sæter, and A. Wallöe. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the scandinavian sarcoma group register. *Eur J Cancer*, 36(6):710–716, 2000.

[147] J. van der Hage, C. van de Velde, J. Julien, J. Floiras, T. Delozier, C. Vandervelden, and L. Duchateau. Improved survival after one course of perioperative chemotherapy in early breast cancer patients. long-term results from the european organization for research and treatment of cancer (eortc) trial 10854. *Eur J Cancer*, 37(17):2184–2193, 2001.

[148] J. C. van Gaal, E. Bastiaannet, M. Schaapveld, R. Otter, J. C. Kluin-Nelemans, E. S. J. M. de Bont, and W. T. A. van der Graaf. Cancer in adolescents and young adults in north netherlands (1989–2003): increased incidence, stable survival and high incidence of second primary tumours. *Ann Oncol*, 20(2):365–373, 2008.

[149] H. van Houwelingen and H. Putter. *Dynamic Prediction in Clinical Survival Analysis*. CRC Press/Chapman & Hall, 2011.

[150] H. C. van Houwelingen. Validation, calibration, revision and combination of prognostic survival models. *Stat Med*, 19(24):3401–3415, 2000.

[151] H. C. van Houwelingen. Dynamic prediction by landmarking in event history analysis. *Scand J Stat*, 34(1):70–85, 2007.

[152] J. van Houwelingen. The role of empirical bayes methodology as a leading principle in modern medical statistics. *Biom J*, 56(6):919–932, 2014.

[153] J. van Houwelingen, R. Brand, and T. Louis. Empirical Bayes methods for monitoring health care quality. `https://www.lumc.nl/sub/3020/att/EmpiricalBayes.pdf`, 2000.

[154] J. C. van Houwelingen and S. Le Cessie. Predictive value of statistical models. *Stat Med*, 9(11):1303–1325, 1990.

[155] V. van Praag, **A. J. Rueten-Budde**, V. Ho, P. Dijkstra, I. C. van der Geest, J. A. Bramer, G. R. Schaap, P. C. Jutte, H. B. Schreuder, J. Ploegmakers, M. Fiocco, and M. van de Sande. Incidence, outcomes and prognostic factors during 25 years of treatment of chondrosarcomas. *Surg Oncol*, 27(3):402–408, 2018.

[156] C. van Walraven and F. A. McAlister. Competing risk bias was common in kaplan-meier risk estimates published in prominent medical journals. *J Clin Epidemiol*, 69:170–173, 2016.

[157] J. Vaupel, K. Manton, and E. Stallard. The impact of heterogeneity in individual frailty on the dynamics of mortality. *Demography*, 16(3):439–454, 1979.

[158] E. von Elm, D. G. Altman, M. Egger, S. J. Pocock, P. C. Gøtzsche, and J. P. Vandenbroucke. The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies. *J Clin Epidemiol*, 61(4):344–349, 2008.

[159] A. E. Wahlquist, L. N. Muhammad, T. L. Herbert, V. Ramakrishnan, and P. J. Nietert. Dissemination of novel biostatistics methods: impact of programming code availability and other characteristics on article citations. *PLOS ONE*, 13(8):1–12, 2018.

[160] J. Werier, X. Yao, J.-M. Caudrelier, G. Di Primio, M. Ghert, A. A. Gupta, R. Kandel, and S. Verma. Evidence-based guideline recommendations on treatment strategies for localized ewing's sarcoma of bone following neo-adjuvant chemotherapy. *Surg Oncol*, 25(2):92–97, 2016.

[161] A. Wienke, K. Christensen, N. Holm, and A. Yashin. Heritability of death from respiratory diseases: an analysis of danish twin survival data using a correlated frailty model. *Stud Health Technol Inform*, 77(77):407–411, 2000.

[162] A. Wienke, K. Christensen, A. Skytthe, and A. Yashin. Genetic analysis of cause of death in a mixture model of bivariate lifetime data. *Stat Modelling*, 2:89–102, 2002.

[163] A. Wienke, N. Holm, A. Skytthe, and A. Yashin. The heritability of mortality due to heart diseases: a correlated frailty model applied to danish twins. *Twin Res*, 4(4):266–274, 2001.

[164] J. Willeumier, M. Fiocco, R. Nout, S. Dijkstra, W. Aston, R. Pollock, H. Hartgrink, J. Bovée, and M. van de Sande. High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survival. *Int Orthop*, 39(5):935–941, 2015.

[165] M. Wolbers, M. T. Koller, J. C. Witteman, and E. W. Steyerberg. Prognostic models with competing risks: methods and application to coronary risk prediction. *Epidemiol*, 20(4):555–561, 2009.

[166] A. Yashin, J. Vaupel, and I. Iachine. Correlated individual frailty: an advantageous approach to survival analysis of bivariate data. *Math Popul Stud*, 5(2):145–159, 1995.

[167] G. Young and R. Smith. *Essentials of Statistical Inference*. Cambridge University Press, 2005.

[168] B. Yu, J. Saczynski, and L. Launer. Multiple imputation for estimating the risk of developing dementia and its impact on survival. *Biom J*, 52(5):616–627, 2010.

[169] G. Zagars, M. Ballo, P. Pisters, R. Pollock, S. Patel, R. Benjamin, and H. Evans. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy. *Cancer*, 97(10):2530–2543, 2003.

[170] G. K. Zagars, M. T. Ballo, P. W. Pisters, R. E. Pollock, S. R. Patel, and R. S. Benjamin. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. *Int J Radiat Oncol Biol Phys*, 56(2):482–488, 2003.

[171] Y. Zheng and P. Heagerty. Prospective accuracy for longitudinal markers. *Biometrics*, 63(2):332–341, 2007.

[172] B. Zhou, J. Fine, A. Latouche, and M. Labopin. Competing risks regression for clustered data. *Biostatistics*, 13(3):371–383, 2012.